Zacks Investment Research
27 Mar 2026, 13:51 UTC · 26w ago
Verdict
Headline takes no side. We score PEN +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Penumbra's STORM-PE trial demonstrated that CAVT combined with anticoagulation is superior to anticoagulation alone in reducing right heart strain for high-risk pulmonary embolism patients.
More positive than 93% of claims this week
Penumbra has launched several new products in 2025, including the Element Vascular Access System and Ruby XL, expanding its market reach in peripheral embolization.
So whatProduct portfolio expansion creates new revenue streams and increases market share.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
The company expects to materially increase revenues and profitability from its international business over the next few years.
More positive than 66% of claims this week
Penumbra faces potential operational risks from unfavorable foreign exchange rates and a dull macroeconomic environment.
So whatMacro headwinds and currency volatility can erode margins and reported earnings for companies with significant international exposure.
More negative than 69% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is seeing robust product portfolio expansion, strong adoption of its CAVT portfolio, and is poised for growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−5.2%
Price is moving against the score
$318.89 vs $336.42 close before publication (Mar 26) · not market-adjusted
PEN chart →
